Header Logo

Connection

Gabriel Pardo to Alemtuzumab

This is a "connection" page, showing publications Gabriel Pardo has written about Alemtuzumab.
Connection Strength

0.045
  1. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020 Nov; 267(11):3343-3353.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.